Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study

References

• Hochberg MC, Tracy JK, Hawkins-Holt M, et al. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl 2):13-16
   Google Scholar
• Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010;30:339-53
   PubMed Web of Science ®Google Scholar
• Alivernini S, Laria A, Gremese E, et al. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Res Ther 2009;11:R163
   PubMed Web of Science ®Google Scholar
• Erickson AR, Mikuls TR. Switching anti-TNF-alpha agents: what is the evidence? Curr Rheumatol Rep 2007;9:416-20
   PubMedGoogle Scholar
• Hyrich KL, Lunt M, Watson KD, et al; for the British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20
   PubMed Web of Science ®Google Scholar
• Scrivo R, Conti F, Spinelli FR, et al. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo 2009;61:107-17
   PubMedGoogle Scholar
• Chatzidionysiou K, Askling J, Eriksson J, et al.; for the ARTIS group. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis 2014: published online 15 January 2014, doi: 10.1136/annrheumdis-2013-204714
   Google Scholar
• Conti F, Scrivo R, Spinelli FR, et al. Outcome in patients with rheumatoid arthritis switching TNF-alpha antagonists: a single center, observational study over an 8-year period. Clin Exp Rheumatol 2009;27:540-1
   PubMed Web of Science ®Google Scholar
• Bingham CO III, Ince A, Haraoui B, et al. Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. Curr Med Res Opin 2009;25:1131-42
   PubMed Web of Science ®Google Scholar
• Cohen G, Courvoisier N, Cohen JD, et al. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23:795-800
   PubMed Web of Science ®Google Scholar
• Furst D, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the OPPOSITE study. Ann Rheum Dis 2007;66:893-9, comment in: Ann Rheum Dis 2007;66:849-51
   PubMed Web of Science ®Google Scholar
• Hansen KE, Hildebrand JP, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;31:1098-102
   PubMed Web of Science ®Google Scholar
• Laas K, Peltomaa R, Kautiainen H, et al. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol 2008;27:927-32
   PubMed Web of Science ®Google Scholar
• van Vollenhoven R, Harju A, Brannemark S, et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis 2003;62:1195-8
   PubMed Web of Science ®Google Scholar
• Van Gestel AM, Prevoo ML, van’t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40, comment in: Arthritis Rheum 1998;41:942-5
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van’t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8
   PubMed Web of Science ®Google Scholar
• van Gestel A, Stucki G. Evaluation of established rheumatoid arthritis. Bailliere’s Best Pract Res Clin Rheumatol 1999;13:629-44
   PubMed Web of Science ®Google Scholar
• van Riel PL, van Gestel AM, Scott DL. EULAR Handbook of Clinical Assessments in Rheumatoid Arthritis. Alphen Aan Den Rijn, The Netherlands: Van Zuiden Communications BV, 2000
   Google Scholar
• Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007;21:662-75
   Web of Science ®Google Scholar
• Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806
   PubMed Web of Science ®Google Scholar
• Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45
   PubMed Web of Science ®Google Scholar
• Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective. J Rheumatol 1993;20:557-60
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form healthy survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s Disease. Clin Gastroenterol Hepatol 2004;2:542-53
   PubMed Web of Science ®Google Scholar
• Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86, erratum in Arthritis Rheum 2007;56:1675
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Klareskog L. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE. Scand J Rheumatol 2007;36:418-23
   PubMed Web of Science ®Google Scholar
• Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007;46:1191-9
   PubMed Web of Science ®Google Scholar
• Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:547-54
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806
   PubMed Web of Science ®Google Scholar
• Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 2004;31:1538-45
   PubMed Web of Science ®Google Scholar
• Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskel Dis 2004;5:36
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:638-43
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Lunt M, Dixon WG, et al; on behalf of the BSR Biologics Register. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology 2008;47:1000-5
   PubMed Web of Science ®Google Scholar
• Smolen JS, van der Heijde DM, St Clair EW, et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset (ASPIRE) study group. Arthritis Rheum 2006;54:702-10
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63
   PubMed Web of Science ®Google Scholar
• van der Laken CJ, Voskuyl AE, Roos JC, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007;66:253-6
   PubMed Web of Science ®Google Scholar